Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Structure

The CAIPM's research contingent is organised into 6 Work Packages:

  • WP1 - Clinical survey of genetic data on Centre's disease areas in Saudi
  • WP2 - Development and implementation of Neural Networks to identify novel drug targets
  • WP3- Biological characterisation of targets identified by WP2 and assay creation
    • WP3a - Structural biology
    • WP3b - Beta cell function / T2D expertise
  • WP4 - Development of chemical probes for potential drug targets, identification of binding sites for drugs
  • WP5 - Implementation of AI methods to optimise drug design

 CAIPM Work flow

The WPs' work feed into each other in numeric order but work continuously to allow the best opportunity to explore as many options as possible given the expectation that many targets will fail early.

There is a management team that organises the Centre's administrative affairs and liaises with the board. The Scientific Director sits on this team, as do some of the WP Leads.

CAIPM has an advisory board comprised of senior faculty from both Oxford and KAU, Chris Molloy (CEO Medicines Discovery Catapult) sits on the board as a neutral, third-party chair.